Concepts (56)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytoreduction Surgical Procedures | 7 | 2024 | 76 | 1.900 |
Why?
|
| Hyperthermia, Induced | 6 | 2024 | 73 | 1.240 |
Why?
|
| Peritoneal Neoplasms | 6 | 2024 | 184 | 1.160 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.840 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 281 | 0.680 |
Why?
|
| Appendiceal Neoplasms | 3 | 2023 | 31 | 0.640 |
Why?
|
| Metaplasia | 1 | 2018 | 37 | 0.630 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 981 | 0.630 |
Why?
|
| Databases, Factual | 2 | 2018 | 850 | 0.590 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 3000 | 0.520 |
Why?
|
| Laparoscopy | 1 | 2022 | 771 | 0.510 |
Why?
|
| Patient Selection | 1 | 2017 | 682 | 0.450 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1149 | 0.400 |
Why?
|
| Axilla | 3 | 2018 | 104 | 0.330 |
Why?
|
| Survival Rate | 6 | 2023 | 1889 | 0.310 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1710 | 0.290 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 220 | 0.270 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 3657 | 0.240 |
Why?
|
| Appendix | 1 | 2023 | 31 | 0.220 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 47 | 0.210 |
Why?
|
| Gastrectomy | 1 | 2022 | 69 | 0.210 |
Why?
|
| Patients | 1 | 2022 | 102 | 0.200 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 72 | 0.180 |
Why?
|
| Humans | 12 | 2024 | 89063 | 0.170 |
Why?
|
| Aged | 4 | 2022 | 19077 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 833 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2022 | 382 | 0.160 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 81 | 0.150 |
Why?
|
| Middle Aged | 4 | 2022 | 25863 | 0.140 |
Why?
|
| Prognosis | 3 | 2023 | 3773 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 158 | 0.140 |
Why?
|
| Mastectomy | 1 | 2018 | 245 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 1194 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2023 | 9003 | 0.120 |
Why?
|
| Peritoneum | 2 | 2024 | 57 | 0.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.110 |
Why?
|
| Surgeons | 1 | 2017 | 247 | 0.110 |
Why?
|
| Female | 4 | 2022 | 46011 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1867 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2022 | 2275 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2001 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2552 | 0.080 |
Why?
|
| Adult | 3 | 2023 | 26507 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 40 | 0.050 |
Why?
|
| Palliative Care | 1 | 2022 | 263 | 0.050 |
Why?
|
| Male | 1 | 2022 | 42251 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2018 | 174 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 245 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 393 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 576 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1662 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 4132 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 1543 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6777 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 6288 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 9237 | 0.020 |
Why?
|